Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Showing 1912 results
March 2020
-
Story People and Culture
Novartis Social Business Careers: improving health in lower income countries
This is the story of how three Novartis colleagues took a career decision to improve health in lower income countries.
-
Featured News
International Women’s Day 2020
To celebrate International Women’s Day we explore how an inclusive environment that values unique and curious minds helps everyone be inspired to innovate every day. -
Story From Our Labs
Advancing medicine through collaboration
In Wendi Yajnik’s quest to find new technologies that could transform medicine, relationships are priority No. 1.
-
Story Discovery
Clinical trial comes together in weeks to address coronavirus
Researchers race to put hydroxychloroquine to the test in a large study.
-
Press release
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million. The PAMAfrica consortium brings… -
Ad hoc release
Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.
Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long…
February 2020
-
Ad hoc release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 23rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5%1 yield and approximately 54% payout of free cash flow Shareholders confirm Dr.… -
Ad hoc release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelle
Les actionnaires approuvent la 23e augmentation consécutive du dividende qui passe à CHF 2.95 (+4%) par action pour l’année 2019, soit un rendement de 3,5%1 et une distribution du free cash-flow… -
Story People and Culture
Parental Leave at Novartis: Alfred’s story
At Novartis, we celebrate life and recognize moments that matter. Alfred Ambatlle shares his experience of parental leave and becoming a father of twins.
-
Press release
Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis
LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust Novartis is responsible for completing Phase I clinical trials and has committed to… -
Story Discovery
Shaping the future of sickle cell disease
Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.
-
Press release
Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)
Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as…